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We report the discovery of conopressin-T, a novel bioactive
peptide isolated from Conus tulipa venom. Conopressin-T
belongs to the vasopressin-like peptide family and displays high
sequence homology to the mammalian hormone oxytocin (OT)
and to vasotocin, the endogenous vasopressin analogue found in
teleost fish, the cone snail’s prey. Conopressin-T was found to
act as a selective antagonist at the human V1a receptor. All pep-
tides in this family contain two conserved amino acids within
the exocyclic tripeptide (Pro7 andGly9), which are replacedwith
Leu7 and Val9 in conopressin-T. Whereas conopressin-T binds
only to OT and V1a receptors, an L7P analogue had increased
affinity for the V1a receptor and weak V2 receptor binding. Sur-
prisingly, replacing Gly9 with Val9 in OT and vasopressin
revealed that this position can function as an agonist/antagonist
switch at the V1a receptor. NMR structures of both conopres-
sin-T and L7P analogue revealed amarked difference in the ori-
entation of the exocyclic tripeptide that may serve as templates
for the design of novel ligands with enhanced affinity for the V1a
receptor.
The vasopressin (AVP)3 and oxytocin (OT) peptides were
originally discovered and identified as neurohypophysial
hormones in mammals (1). In humans, AVP acts via three
vasopressin receptors (vascular V1aR, pituitary V1bR, and
renal V2R), whereas OT acts via one OT receptor (OTR). All
targets are members of the G protein-coupled receptor fam-
ily (2). Peripherally, they regulate water balance, the control
of blood pressure, and contraction of uterine smooth muscle
and mammary myoepithelium (3). Centrally, these peptides
affect levels of aggression, depression, and young parent
bonding (4–6). Endogenous analogues of OT and AVP have
been reported in nonmammalian vertebrates, annelids, mol-
luscs, and insects, suggesting an old lineage for these pep-
tides (7). Surprisingly, two variants were also found in the
venom of predatory cone snails. The original discovery of
these two AVP analogues, named conopressins, was based
on the characteristic “scratching” effect observed upon
intracerebral injection into mice (8). Although the
sequences of conopressins are similar to vasopressin itself,
they have an additional positive charge in position 4, which is
only found in two other endogenous vasopressin analogues,
cephalotocin (Octopus vulgaris) and annetocin (Eisenia foe-
tida). Conopressin-S was isolated from Conus striatus,
whereas conopressin-Gwas first isolated fromConus geogra-
phus venom but later found in Conus imperialis venom as
well as in tissue extracts of the nonvenomous snails Lymnea
stagnalis and Aplysia californica and the leech Erpobdella
octoculata (9–11).
Molluscs of the genus Conus produce bioactive peptides in a
combinatorial fashion. As demonstrated for the snake toxins
(12), most conotoxins or conopeptides are believed to be
derived from an endogenous structural template (13). Because
conopressin-G is widely distributed, it may represent the
endogenous hormone in Gastropods and Annelids. However, a
role in prey capture has also been proposed (14).
In this study, we report the discovery of conopressin-T iso-
lated fromConus tulipa venom. Pharmacological characteriza-
tions of Con-T across human receptors revealed that it is a
selective V1a antagonist, with partial agonist activity at the OT
receptor and no detectable activity at V1b andV2 receptors. The
exocyclic tripeptide segment of conopressin-T shows unusual
sequence divergence. L7P-Con-T had increased affinity at the
V1a receptor but minimal effect on the selectivity profile across
all human receptors compared with Con-T. Interestingly,
replacing Gly9 with Val9 in OT and AVP converted these pep-
tides from full agonist to full antagonist at the V1a receptor,
demonstrating the role of position 9 as an antagonist switch in
these peptides. Finally, the NMR structures of conopressin-T
and its L7P analogue provide new templates for the design of
novel pharmacological agents with enhanced activity at the V1a
receptor.
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EXPERIMENTAL PROCEDURES
Materials—t-Butoxycarbonyl-protected amino acids and
reagents used during chain assembly and HPLC purification
(dimethylformamide, dichloromethane, acetonitrile, and triflu-
oroacetic acid) were peptide synthesis grade purchased from
Auspep (Melbourne, Australia) and Novabiochem (San Diego,
CA). 4-methylbenzhydrylamine-NH2 resin was obtained from
AppliedBiosystems (FosterCity, CA).Most standard chemicals
were purchased from Sigma, Roche Applied Science, orMerck,
unless otherwise indicated. AVP and OT came from Bachem
(Bubendorf, Switzerland), and fetal calf serumwas from Sigma.
Myo-[2-3H]inositol was from PerkinElmer Life Sciences. Min-
imal essential medium and Dulbecco’s modified Eagle’s
medium were purchased from Invitrogen, and inositol-free
Dulbecco’s modified Eagle’s medium came from ICN Bio-
chemicals (Orsay, France). Dowex AG1-X8 formate form 200–
400 mesh was purchased from Bio-Rad.
Human V1a and V1b MTS membranes from HEK293 cells,
human V2 MTS membranes from CHO-K1 cells, [3H]OT
([tyrosyl-2,6-3H]oxytocin; 40 Ci/mmol), 125I-linear vasopressin
V1a receptor antagonist ([125I]phenylacetyl-DTyr(Me)-Phe-
Gln-Asn-Arg-Pro-Arg-Tyr-NH2; 2,200 Ci/mmol), [3H]AVP
([Arg8,tyrosyl-3,5-3H]vasopressin; 19.4 Ci/mmol), FlashBlueTM
GPCR scintillation beads, Betaplate Scintillant, GF/B filter-
mats, sample bags, and TopSeal-A 96-well plate sealing film
were from PerkinElmer Life Sciences, [Arg8]vasopressin from
Auspep (Melbourne, Australia), Costar 96-well white polysty-
rene plates with clear flat bottoms from Corning Glass,
pcDNA3.1/V5-His©TOPOTA expression kit, ThermalAceTM
DNA polymerase, SuperScriptTM III RNase H-reverse tran-
scriptase, Red hot TaqDNA polymerase, F-12 nutrient mixture
(HAM) from Invitrogen, QuikChangeTM XL site-directed
mutagenesis kit fromStratagene (La Jolla, CA), human placenta
total RNA from Ambion (Austin, TX), trypsin-Versene
(EDTA), and Serum Supreme from Cambrex Biosciences
(Walkersville, MD), all primers and oligonucleotides from
Sigma, TransIT-CHO transfection kit from Mirus (Madison,
WI), andCHO-K1 cells from theAmericanTissueCulture Col-
lection (Manassas, VA).
Isolation and Sequencing—Specimens of Conus tulipa were
collected from the Great Barrier Reef, Australia. Venom ducts
were dissected, and crude venom prepared as previously
described (15). Initial fractionation of the venom was carried
out by RP-HPLC, and fractions were stored at 4 °C until further
use.
Conopressin-T was purified from fraction 30 using a 1% lin-
ear gradient of 0–60% solvent B in A over 60 min (A  0.05%
trifluoroacetic acid (aqueous); B 0.045% trifluoroacetic acid,
90% acetonitrile) on an analytical C18 Phenomenex column.
The flow rate was 1ml/min, and the absorbancewasmonitored
at 214 nm. N-terminal sequencing was carried out on an
Applied Biosystems Procise HT Protein Sequencer (BRF, New-
castle, Australia) using20 pmol of purified peptide.
Peptide Synthesis—Conopressin-T and analogues were syn-
thesized using the method described in Ref. 13, with minor
modifications. Briefly, conopressin-T and L7P-conopressin-T
were synthesized manually using t-butoxycarbonyl chemistry
with in situ neutralization protocols (16) on a 0.5-mmol scale
for residues 9 and 8. The peptide was then nitrogen-dried and
split into two syntheses of 0.25 mmol for the remaining 7 resi-
dues of conopressin-T and L7P-conopressin-T. After HF cleav-
age, the crude peptides were purified by semipreparative RP-
HPLC using a linear gradient of 0–60% B at 3 ml/min while
monitoring UV absorbance at 214 nm. Air oxidation was car-
ried out by dissolving 10mg of the crude peptides in 45ml of 0.1
M NH4HCO3 (pH 8.25) with vigorous stirring at room temper-
ature for 1 h. Whereas L7P-conopressin-T dissolved readily at
concentrations up to 0.5 mg/ml, conopressin-T was found to
aggregate instantly. To overcome this, 1 mg of reduced cono-
pressin-T was first dissolved in a 2:1 ratio of solution A and B
and then slowly added to the oxidation buffer. Prior to purifi-
cation, the solution was acidified to pH 3 with neat trifluoro-
acetic acid and analyzed by analytical C18 HPLC and electro-
spray-MS. Oxidized conopressin-T and L7P-conopressin-T
were then purified by semipreparative RP-HPLC using the
same chromatographic conditions as above. Pure fractions, as
determined by analytical RP-HPLC and mass spectrometry,
were pooled and lyophilized. Stock solutions of conopressin-T
and L7P-conopressin-T were made in MilliQ water and quan-
tified by analytical HPLC using a commercial AVP standard.
Cloning of Human OT Receptor—A 1.3-kb fragment of OT
cDNA, containing the full coding region of the human OT
receptor, was isolated from human placental cDNA con-
structed from total placental RNA using SuperScriptTM III
reverse transcriptase. The following forward (5-GGTAGAG-
GATTCCCGCTCATTTG-3) and reverse (5-GGGGAGG-
GATACAAACTGATAGG-3) primerswere used to isolate the
DNA fragment. This fragmentwas subcloned into themamma-
lian expression vector pcDNA3.1/V5-his-TOPO. Following
sequence analysis, 8 nucleotide changes were found over the
published OT sequence (NM_000916) encoding 7 amino acid
changes with one change being conserved. The nucleotide
changes were T47C, A281G, A256C, G532C, T646C, and
A1121G, which correspond to amino acid changes of V16A,
H73R, M86L, G178R, F216L, and N374S. These changes were
mutated to the published sequence using a QuikChangeTM XL
site-directed mutagenesis kit.
OT Receptor Expression and Membrane Preparation—DNA
was prepared and used for transfection in CHO-K1 cells.
CHO-K1 cells were propagated in 150-mm plates with F-12
medium containing 10% Serum Supreme at 37 °C in a humidi-
fied atmosphere with 5% CO2. Transient transfection was per-
formed with an appropriate plasmid using the TransIT-CHO
transfection reagent method. Briefly, the method involved
combining TransIT-CHO reagent (72 l) in serum-free F-12
medium incubated for 5 min at room temperature. Following
the addition of receptor plasmid (24g), thismixture was incu-
bated for 10 min at room temperature. CHOMojo reagent (16
l) was added to the mixture and incubated for 15 min at room
temperature prior to the addition to the cells.
The transfected cells were harvested within 24 h by the fol-
lowing method. Confluent 150-mm plates were washed with
phosphate-buffered saline (10mMphosphate buffer, pH 7.4, 2.7
mM KCl, 137 mM NaCl), harvested by scraping into ice-cold
harvest buffer (50mMTris-HCl, pH 7.4, 5mMMgCl2), followed
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by homogenization with a Polytron homogenizer and centrifu-
gation at 100 g for 10 min at 4 °C. Supernatants were recov-
ered and centrifuged at 22,000  g for 1 h at 4 °C. Membrane
pellets were resuspended in 0.5ml of ice-cold assay buffer A (50
mMTris-HCl, pH7.4, 5mMMgCl2, 0.1%bovine serumalbumin,
containing 10% glycerol and aliquots stored at80 °C until use.
Receptor Binding Studies—Receptor binding assayswere per-
formed using FlashBlueTM GPCR scintillation beads. Flash-
BlueTM GPCR beads are 3-m polystyrene scintillating beads
with wheat germ agglutinin covalently attached on the surface.
These beads allow development of a homogeneous GPCR
radioligand binding assay using cellular membranes. Briefly,
FlashBlueTM GPCR SPA binding assays were performed in
96-well white polystyrene plates with clear flat bottoms
(Costar). Radioligand (OTR [3H]OT (2 nM), V1a 125I-labeled
linear V1a antagonist (21 pM), V1b [3H]AVP (0.5 nM), V2
[3H]AVP (0.85 nM)) was added to each membrane preparation,
followed by the addition of various concentrations of compet-
ing compounds (1 pM to 10 M) in a total volume of 80 l
containing assay buffer A or B (50 mM Tris-HCl, pH 7.4, 0.1%
bovine serum albumin, and either 5 mM MgCl2 (A) or 10 mM
MgCl2 (B)) (OT andV2 assay, bufferA; V1a andV1b assay, buffer
B). The final reaction volume per well comprised 20 l of com-
pound/buffer, 20 l of FlashBlueTM GPCR beads (OTR, V1a,
and V2, 100 g; V1b, 200 g), and 20 l of membrane, and the
assay was initiated by the addition of 20 l of radioligand. The
plate was then sealed with TopSeal-A sealing film and incu-
bated with shaking for 1 h at room temperature. Radioligand
binding was then assessed for 30 s/well on a 1450 Microbeta
scintillation counter (Wallac).
All binding data were analyzed using GraphPad PRISM
(GraphPADSoftware, Inc., SanDiego,CA). Eachdata pointwas
performed in triplicate and derived from at least three separate
experiments. The inhibitory dissociation constant (Ki) was cal-
culated using the following formula: Ki  IC50/(1  [L]/Kd),
where [L] is the concentration of radioligand present, and Kd is
the dissociation constant of radioligand (17).
Inositol Phosphate Assays—Inositol phosphate accumulation
was determined as previously described (18). Briefly, CHO cells
stably transfected with AVP/OT receptors were plated at
100,000 cells/well. Cells were grown for 24 h in their respective
culture medium (see above) and further incubated for another
24-h period in a serum- and inositol-free medium supple-
mented with 1 Ciml1 myo-[2-3H]inositol. Cells were then
washed twice with Hanks’ buffered saline medium, incubated
for 15 min in this medium supplemented with 20 mM LiCl, and
further stimulated for 15minwith increasing concentrations of
analogues to be tested. The reaction was stopped by adding
perchloric acid (5%, v/v). Total inositol phosphates (IPs) accu-
mulatedwere extracted and purified on aDowexAGI-X8 anion
exchange chromatography column and counted.
NMR Spectroscopy—Samples for 1H NMR measurements
contained1mM peptide in 95%H2O, 5%D2O (v/v) at pH3.
Spectra were recorded at 290 K on a Bruker AVANCE-600
spectrometer. Two-dimensional NMR spectra were recorded
in phase-sensitive mode using time-proportional phase incre-
mentation for quadrature detection in the t1 dimension (19,
20). The two-dimensional experiments consisted of a TOCSY
using a MLEV-17 spin lock sequence with a mixing time of 80
ms, DQF-COSY, and NOESY with mixing times of 200–300
ms. Solvent suppression was achieved using a modified
WATERGATE sequence. Spectra were acquired over 6024 Hz
with 4096 complex data points in F2 and 512 increments in the
F1 dimension. 3JHN-H coupling constants weremeasured from
a one-dimensional spectrum or from the DQF-COSY spec-
trum. Spectra were processed on a Silicon Graphics Indigo
work station using XWINNMR (Bruker) software. The t1
dimension was zero-filled to 1024 real data points, and 90°
phase-shifted sine bell window functions were applied prior to
Fourier transformation.
Structure Calculations—Preliminary structures were calcu-
lated using a torsion angle simulated annealing protocol within
the program DYANA (21). Final structures were calculated
using simulated annealing and energy minimization protocols
within CNS version 1.1 (22). The starting structures were gen-
erated using random (,) dihedral angles and energy-mini-
mized to produce structures with the correct local geometry. A
set of 50 structures was generated by a torsion angle simulated
annealing protocol (19, 20). This protocol involved a high tem-
perature phase comprising 4000 steps of 0.015 ps of torsion
angle dynamics, a cooling phase with 4000 steps of 0.015 ps of
torsion angle dynamics during which the temperature was low-
ered to 0 K, and finally an energy minimization phase compris-
ing 500 steps of Powell minimization. Structures consistent
with restraints were subjected to further molecular dynamics
and energy minimization in a water shell, as described by Linge
and Nilges (23). The refinement in explicit water involved the
following steps. First, heating to 500 K via steps of 100 K, each
comprising 50 steps of 0.005 ps of Cartesian dynamics. Second,
2500 steps of 0.005 ps of Cartesian dynamics at 500 K before a
cooling phase where the temperature was lowered in steps of
100 K, each comprising 2500 steps of 0.005 ps of Cartesian
dynamics. Finally, the structures were minimized with 2000
steps of Powell minimization. Structures were analyzed using
PROMOTIF (24) and PROCHECK-NMR (25).
RESULTS
Isolation and Sequencing of Conopressin-T—Apeptidewith a
monoisotopic mass of 1107.54 Da was purified from C. tulipa
venom (Fig. 1, A–C). The Tris(2-carboxyethyl)phosphine-re-
duced peptide displayed a mass of 1109.5 Da, suggesting the
presence of one disulfide bond (data not shown). N-terminal
sequencing produced the sequence CYIQNCLRVwith a calcu-
lated mass of 1110.53 Da, consistent with one disulfide bond
(2 Da) and C-terminal amidation (1 Da). A BLAST search
revealed that this sequence belonged to the vasopressin peptide
family characterized by a disulfide-containing ring (residues
1–6) and a short exocyclic C-terminal tripeptide (residues
7–9). Conopressin-T had 7 of 9 residues identical to vasotocin
(AVT), including the first six residues also found in oxytocin
and mesotocin, and Arg8 known to be essential for the pressor
activity in vasopressin. However, two highly conserved resi-
dues, Pro7 andGly9, found in other vasopressin-like peptides as
well as conopressin-G and conopressin-S are modified to Leu7
and Val9 in conopressin-T. De novo mass spectrometry
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sequencing (data not shown) unambiguously confirmed the
sequence of Con-T as CYIQNCLRV-NH2.
Synthesis of Conopressin-T and L7P-Conopressin-T—Con-T
and its analogues were synthesized on 4-methylbenzhy-
drylamine resin using solid-phase peptide synthesis t-butoxy-
carbonyl chemistry to further validate the primary sequence
and allow characterization of its biological activity. Lyophilized
crude peptides from HF cleavage were dissolved in 0.5% triflu-
oroacetic acid and analyzed on analytical C18 Phenomenex RP-
HPLC column. The chromatograms and electrospray-MS
revealed that the syntheses contained 90% of the expected
products; consequently, the oxidation was carried out directly
on the crude peptides following the conditions described under
“Experimental Procedures.” During synthesis, we noticed that
the replacement of Leu7 by Pro7 had a marked effect on solu-
bility. L7P-Con-T dissolved readily in oxidation buffer to 0.5
mg/ml, whereas Con-T aggregated instantly in this solvent.
This difference suggested that a Leu or a Pro at position 7 sig-
nificantlymodified the physical properties of the peptides. Oxi-
dized synthetic and native Con-T were indistinguishable when
co-injected in a C18 Phenomenex analytical RP-HPLC column
(Fig. 1D).
Conopressin-T and L7P-Conopressin-T Are Selective V1a
Receptor Antagonists—Con-T and L7P-Con-T were tested
for their ability to displace radioligand from human AVP and
OT receptors expressed in HEK and CHO cells (Fig. 2A and
Table 1). Con-T showed thehighest affinity for humanOTR (Ki
108 nM) and V1aR (Ki 319 nM) and no detectable activity at V1b
andV2 receptors at up to 10Mpeptide. In contrast, L7P-Con-T
was 8-fold more potent than Con-T at the V1aR (Ki  37 nM)
but had similar affinity for OTR (Ki 132 nM). L7P-Con-T was
also found to have a weak effect at V2R (Ki 1.8 M), whereas
no displacement of radioligand was detected at the V1bR at up
to 10 M peptide. For comparison, we also tested the activity of
conopressin-S (Con-S) across these receptors. Con-S does not
bind to V2R (up to 10 M peptide), has similar affinity for OTR
(Ki 175 nM) but is less potent at V1a (Ki 827 nM). In contrast
to Con-T and L7P-Con-T, Con-S binds with high affinity to
V1bR (Ki  8.3 nM), although the displacement of specific
[3H]AVP binding was incomplete (a 30–40% resistant compo-
nent remained; see Fig. 2A). Therefore, conopressin-T, -S, and
-L7P have distinct pharmacological profiles on human recep-
tors, with the lack of effect of Con-T on radioligand binding to
both V1b and V2 receptors being unique (supplemental Fig. 1).
The functional properties of Con-T and L7P-Con-T were
investigated on CHO cells expressing human receptors (Fig. 2B
and Table 2). Con-T did not stimulate phospholipase C activity
in cells expressing V1aR at10M peptide. However, Con-T at
10 M showed partial agonist activity at the V1bR and OTR,
producing 9 and 22% of AVP and OTmaximal activity, respec-
tively. L7P-Con-T displayed a similar profile, with no agonist
activity at the V1aR at10M and partial agonist activity at the
V1bR and OTR (4 and 28% of AVP and OT maximal activity,
respectively) at 10 M peptide. In contrast, both Con-T and
L7P-Con-T induced a potent and concentration-dependent
inhibition of AVP-stimulated IP production in CHO cells
expressing V1aR, with Kinact values of 329 and 90 nM, respec-
tively (Table 2). These values correlated well with the binding
affinities. Thus, both peptides are full antagonists at the human
V1aR subtype and weak partial agonists for the V1bR and OTR
(Fig. 2B). Due to the absence of significant binding to V2R, the
functional activity of Con-T and L7P-Con-T was not investi-
gated on this subtype.
Gly93 Val Replacement in OT and AVP Acts as an Antago-
nist Switch at the V1a Receptor—L7P-conopressin-T and vaso-
tocin differs only at position 9, yet L7P-conopressin-T acts as a
full antagonist at the V1a receptor (Fig. 2B), whereas the closely
related vasotocin is known to function as an agonist (29). To
investigate if the Val9 modification in conopressin-T could
switch agonist to antagonist activity in related peptides, we
tested this modification in OT and AVP. First, the binding
properties of these analogues were assessed on human recep-
tors (Fig. 3A and Table 1). G9V-AVP was equipotent at V1aR
and V2R (25 nM) and 5–7-fold less potent at the OTR and
V1bR (114 and 170 nM, respectively). Compared with AVP,
G9V-AVP affinity ranged from 5-fold less at V2R to 2000-fold
less atV1bR. In contrast, G9V-OTwas equipotent at theV1a and
OT receptors (465 nM), whereas it was unable to fully displace
radioligands at the V1b and V2 subtypes at concentrations up to
10 M. Compared with OT, G9V-OT affinity ranged from
13-fold less at V1aR to 309-fold less at OTR.
The functional properties of G9V-AVP and G9V-OT were
investigated on CHO cells expressing human receptors (Fig. 3B
FIGURE 1. Purification of conopressin-T. A, RP-HPLC chromatogram
showing the complexity of crude C. tulipa venom. The arrow indicates
conopressin-T with a shell of C. tulipa shown in inset. B, fraction 30 con-
tains conopressin-T, a novel bioactive peptide with a molecular mass of
1107.5 Da. C, purification to homogeneity of native conopressin-T from
fraction 30. D, co-elution of native and synthetic conopressin-T. Both pep-
tides elute at indistinguishable times.
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and Table 2). Both peptides failed to stimulate phospholipase C
activity in cells expressing V1aR at 10 M peptide. However,
G9V-AVP and G9V-OT both acted as partial agonists at the
OTR, eliciting5–10% and25–30% of OTmaximal activity,
respectively. In contrast, both peptides induced a potent and
concentration-dependent inhibition ofAVP-stimulated IP pro-
duction in CHO cells expressing V1aR. The affinities (Kinact) of
G9V-AVP (40 nM) and G9V-OT (391 nM) correlate well with
the binding data at the V1a receptor (25 and 466 nM, respec-
tively). Clearly, theG9V replacement shifted the activity of both
AVP andOT from full agonist to full
antagonist at the V1aR, supporting
the hypothesis that position 9 can
act as a functional switch at the V1a
receptor.
Solution Structure of Con-T and
L7P-Con-T—NMR spectral assign-
ments of both peptides were made
using established techniques (26).
The chemical shifts in the amide
region are well dispersed, and
restraints derived from the NOESY
spectra allowed determination of
well defined structures. Analysis of
the nuclear Overhauser effects indi-
cated that the proline residue in
L7P-Con-T is predominantly in a
trans conformation based on the
strong nuclear Overhauser effects
between theH of Cys6 and theHs
of Pro7. In addition, there is evi-
dence of a minor conformation in
the L7P-Con-T spectra, including a
second proline spin system. How-
ever, thisminor conformation could
not be assigned because of its low
intensity andmissing peaks. It is not
uncommon for small peptides to
have prolines adopting mixed cis/
trans conformations, which proba-
bly explains the second spin system
observed.
The three-dimensional struc-
tures of conopressin-T and its L7P
analogue were calculated using a
simulated annealing protocol in
CNS. The resulting families of
structures had good structural and energetic statistics, as
shown in Table 3. An ensemble of the 20 lowest energy struc-
tures for each peptide is shown in Fig. 4A. Analysis of the struc-
tures of each peptide with PROMOTIF (24) indicated that the
major structural feature is a -turn between residues 4 and 7.
The structures of conopressin-T and L7P overlaid well over the
defined regions of the structure (rootmean square deviation for
the backbone atoms of residues 1–6 is 0.52 Å). Although the
C-terminal residues are disordered, the directions of the C-ter-
minal tails clearly differ between the two structures as shown in
Fig. 4, B and C.
DISCUSSION
Con-T isolated from C. tulipa venom is a novel vasopressin-
like peptide. Investigation of its biological activity on human
receptors revealed that Con-T acted selectively at V1a and OT
receptors. Functional studies demonstrated that Con-T was a
full antagonist at V1aR and a partial agonist at OTR. The phar-
macological profile of an L7P analogue was similar but for
increased affinity for the V1aR. The partial agonist activity of
both peptides at OTR indicates incomplete signaling through
FIGURE 2. Binding and functional properties of Con-T and L7P-Con-T on human vasopressin and oxyto-
cin receptors. A, Con-T (), Con-S (‚), and L7P-Con-T (E) displacement of radioligands fromOT, V1a, V1b, and
V2 receptors expressed in CHO cells. Control peptideswere oxytocin () for theOTR and vasopressin () for all
AVP receptors. B, functional properties of Con-T () and L7P-Con-T (E) on human receptors. CHO cells stably
transfected with V1aR (A) or OTR (B) were grown inmyo-[2-
3H]inositol medium and IP accumulationmeasured
andexpressedas apercentageof levels stimulatedbyAVPandOT. Results are themeanS.E. of three separate
experiments, each performed in triplicate.
TABLE 1
Binding affinities (Ki, nM) on human vasopressin and oxytocin
receptors
Compound V1aR V1bR V2R OTR
Con-T 319 15 10,000 10,000 108 9
L7P-Con-T 37 2 10,000 1836 392 132 10
Con-S 827 76 8.3 1.6 10,000 175 13
AVP 0.6 0.02 0.085 0.01 4.9 0.32 110 25
G9V-AVP 25 2 170 22 24 3 114 35
OT 37 3 222 22 823 122 1.5 0.42
G9V-OT 466 43 10,000 10,000 464 171
Values are mean  S.E. obtained from at least three separate experiments, each
performed in triplicate.
SAR of Conopressin-T
7104 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 11•MARCH 14, 2008
the associatedGprotein (Gq/11, Gi/0) perhaps because they bind
and trap the OT receptor in a conformation that is unable to
signal fully. Similarly, OT and AVP act as partial agonists on
vasopressin and oxytocin receptors, respectively (27).
The sequence of Con-T differs significantly from the previ-
ously reported conopressin-G and Con-S. First, the additional
positively charged residue at position 4, which was thought to
be characteristic of conopressins, is
absent in Con-T. Interestingly, and
probably ecologically and evolu-
tionary relevant, Con-T has 7 of 9
residues (including the disulfide
containing ring) identical to vasoto-
cin, the teleost fish equivalent. In
light of our pharmacological results,
and since C. tulipa preys on fish,
Con-T might specifically target
teleost AVT receptors. So far, the
only cloned receptor in teleost fish
appears to be pharmacologically
comparable with the mammalian
V1a and oxytocin receptors (28).
This receptor controls the arterial-
venous flows and is particularly
important in gill hemodynamics
and consequently respiration. How-
ever, conopressin-G and Con-S
were found to be only moderately
active on fish vasotocin receptor
(29). Animal toxins usually shut
down vital functions by blocking
membrane receptors rather than by
activating them, and although
Con-T is yet to be tested on this fish
receptor, it may act as an antagonist
as demonstrated here for the human
V1a receptor. Alternatively, Con-T
may also act synergistically with
other lethal peptides present in the
venom and/or modify the behavior
of the fish to reduce the risk of injury
to the cone snail. Interestingly, spe-
cific localization of staining for
vasotocin in the brain of zebrafish
was found to correlate with aggressive behavior (dominant ver-
sus subordinate social status) (30), and an antagonist might be
expected to reduce such behavior. Other conopeptides are
known to act centrally in fish, which have a leaky blood-brain
barrier (31).
Recently, an unusual -carboxyglutamate at position 8 in the
sequence of conopressin-Vil from the venomofConus villepinii
FIGURE3.BindingandfunctionalpropertiesofG9V-OTandG9V-AVPonhumanreceptors.A,G9V-AVP()and
G9V-OT (ƒ) displacement of radioligands fromOT, V1a, V1b, and V2 receptors expressed in CHO cells. Control pep-
tides were oxytocin () and vasopressin (f) for all human receptors. B, functional properties of G9V-OT (ƒ) and
G9V-AVP () onhuman receptors. CHOcells stably transfectedwithV1aR (left) orOTR (right)weregrown inmyo-[2-
3H]inositolmedium, and IPaccumulationwasmeasuredandexpressedas apercentageof levels stimulatedbyAVP
andOT. The results are themean S.E. of three separate experiments, each performed in triplicate.
TABLE 2
Antagonist and agonist actions of Con-T, L7P-Con-T, G9V-AVP, and G9V-OT on IP signaling through human vasopressin and oxytocin
receptors
Compound V1aR V1bR OTR
Con-T No agonist activity at 10 M
(1 7% of AVP maximum activity)
Weak agonist activity
(9 3% of AVP max activity at 10 M)
Partial agonist (22 3% of OT maximum activity;
Kact 37 30 nM)
Antagonist, Kinact 329 58 nM No antagonist activity at 10 M No antagonist activity at 10 M
L7P-Con-T No agonist activity at 10 M Weak agonist activity at 10 M
(4 2% of AVP max activity)
Partial agonist (28 3% of OT max activity;
Kact 16 nM)
Antagonist, Kinact 90 12 nM No antagonist activity at 10 M No antagonist activity at 10 M
G9V-AVP No agonist activity at 10 M Partial agonist (5–10% of OT maximum activity;
Kact 320 145 nM)
Antagonist, Kinact 40 10 nM NDa No antagonist activity at 10 M
G9V-OT No agonist activity at 10 M Partial agonist (25–30% of OT maximum activity;
Kact 124 37 nM)
Antagonist, Kinact 391 85 nM ND No antagonist activity at 10 M
aND, not determined.
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has been reported, but its biological
activity was not determined (32).
The discovery ofmultiple conopres-
sin sequences supports the theory
that the scaffold of the original vaso-
pressin-like endogenous peptide in
Conus has evolved for more special-
ized use in the venom (14).
Finally, the exocyclic tripeptide of
Con-T has a Leu in position 7 and a
Val in position 9. To our knowledge,
Con-T is the first naturally occur-
ring vasopressin-like peptide with
substitutions at these positions
(Table 4). Although substitutions
within the tocin ring and at position
8have been largely investigated over
the past 50 years using natural and
nonnatural amino acids, there has
been limited study on positions 7
and 9, probably because of their
absolute conservation in this pep-
tide family. AVT acts as an agonist
on AVP receptors (33), and since
L7P-Con-T differs from AVT only
at position 9 and acts as a V1a antag-
onist, it appears thatmodification at
this position alone can switch pep-
tide activity from agonist to antago-
nist. In support of this hypothesis,
the modification G9V in OT and
AVP indeed switched their activity
to a full antagonist at the V1a recep-
tor. Thus, all endogenous peptides
in the AVP-like family have a Gly9
(see Table 4) and act as agonists on
their respective receptors, whereas
FIGURE 4. Three-dimensional structures of Con-T (left; BMRB code 2007) and L7P-Con-T (right; BMRB
code 2008). A, superimposition of the 20 lowest energy structures. B, ribbon representation showing the
backbone trace and cysteine connectivity (yellow). C, stick representation for each representative
structure.
TABLE 3
NMR and refinement statistics for conopressin-T and L7P-conopressin-T
Conopressin-T L7P-Conopressin-T
NMR distance and dihedral constraints
Total NOE 49 42
Intraresidue 5 5
Sequential (i j 1) 30 26
Medium range (i j	 4) 12 10
Long range (i j 5) 2 1
	 restraints 7
Structure Statistics
Violations (mean and S.D.)
Distance constraints (Å) 0.06 0.004 0.06 0.016
Dihedral angle constraints (degrees) 0.49 0.43 0.20 0.22
Maximum dihedral angle violation (degrees) 3 3
Maximum distance constraint violation (Å) 0.3 0.3
Deviations from idealized geometry
Bond lengths (Å) 0.004 0.0001 0.004 0.0005
Bond angles (degrees) 0.52 0.03 0.47 0.06
Impropers (degrees) 0.37 0.07 0.36 0.07
Average pairwise root mean square deviationa (Å)
Backbone atoms (residues 1–6) 0.34 0.14 0.55 0.28
Heavy atoms (residues 1–6) 1.68 0.45 1.61 0.38
a Pairwise root mean square deviation was calculated among 20 refined structures.
SAR of Conopressin-T
7106 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 11•MARCH 14, 2008
Con-T, L7P-Con-T, G9V-OT, G9V-AVP, and a synthetic OT
analogue with a Tyr9 (34) act as antagonists. In contrast, all
Val9-containing peptides investigated here acted as partial ago-
nists at the OT receptor.
The three-dimensional structures of conopressin-T and its
L7P analogue were determined using NMR spectroscopy.
Although the peptides are only 9 residues in length,well defined
structures were determined for residues 1–6, presumably as a
result of the constraints imposed by the disulfide bond between
Cys1 and Cys6. The C-terminal regions are disordered but are
oriented differently between the two peptides, indicating that
Leu7 has a significant influence on the overall structure of cono-
pressin-T. This structural shift probably contributes to the rel-
atively poor solubility of Con-T. Given that the orientation of
the exocyclic residues is influenced by Pro7, it appears that this
relatively short stretch of peptide acts independently to deter-
mine peptide activity, since the pharmacological profiles of
Con-T and L7P-Con-T are somewhat similar.
Comparison of the Con-T and L7P-Con-T structures with
oxytocin and vasopressin highlights the similarity between all
of the structures (supplemental Fig. 2). In particular, the loop
between the two cysteine residues is structurally similar, with
rootmean square deviations of less than 1.5 Å for all structures.
TheC-terminal tails of Con-T and L7P-Con-T, although some-
what disordered, do not overlay well with the tail region of
vasopressin or oxytocin. The proline residue in L7P-Con-T is in
a trans conformation, but there is evidence for a minor confor-
mation that may originate from a cis proline isomer. The pro-
line geometry in OT and AVP has been extensively studied,
with small percentages (10%) of cis isomers in the solution
conformations of these molecules (35). This finding is consist-
ent with the current study as the population of the minor
conformation of L7P-Con-T is 7% based on relative peak
intensities. Previous studies have shown that a cis/trans con-
formational change plays a role in OT receptor binding and
activation (36), but significant differences are not observed
for the affinity of Con-T and L7P-Con-T for the OTR, sug-
gesting that cis/trans isomerization is less important for the
affinity of these peptides.
TheV1a receptorwas recently reported to play amajor role in
spatial memory (37), heart hypertrophy (38), and hyperfiltra-
tion (39). Selective inhibition of this receptor subtype may
therefore have important therapeutic applications. The antag-
onist action of conopressin-T, aswell as the determination of its
three-dimensional structure, offer novel insights into the struc-
ture-activity relationship within the vasopressin peptide family
that may guide the synthesis of novel analogues modified at
positions 7 and 9 toward the design of highly selective V1a
antagonists.
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